

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/517,362
				Filing Date	November 30, 2004
				First Named Inventor	Henrik H De Nijs et al.
				Art Unit	1617
				Examiner Name	Hui, San Ming R.
Sheet	1	of	1	Attorney Docket Number	2002.732US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	1.	DE 1013284	08-08-1957	Schering AG		✓
	2.	GB 845442	08-24-1960	Schering Aktien		
	3.	EP 129 947	01-02-1985	World Health Org		
	4.	DE 19613698	01-23-1997	Schering AG		✓
	5.	ZA 9606083	07-17-1996	Schering Aktien		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	6.	Guerin et al., "Inhibition of Spermatogenesis in Men Using Various Combination of Oral Progestagens and Percutaneous or Oral Androgens," <i>International Journal of Andrology</i> 11 (1988) 187-199.	
	7.	Johnson, A., "Aliphatic Esters of 6,6-Difluoro-17 β -Hydroxy-17-Ethynyl-4-Estren-3-One (6,6-Difluoronorethindrone) and (\pm)-6,6-Difluoro-13 β -Ethyl-17 β -Hydroxy-17-Ethynyl-4-Gonen-3-One (\pm)-6,6-Difluoronorgestrel," <i>Steroids</i> 20 (1972) 263-267.	
	8.	McPhail et.al., "The assay of progesterin," <i>J. of Physiology</i> 83, (1934) 145-156.	
	9.	Shafiee et.al., "LONG-ACTING CONTRACEPTIVE AGENTS: ALIPHATIC AND ALICYCLIC CARBOXYLIC ESTERS OF LEVONORGESTREL," <i>Steroids</i> 41 (1983) 349-359.	
	10.	Watson et al., "LONG-ACTING CONTRACEPTIVE AGENTS: ESTERS OF NORETHISTERONE WITH α AND/OR β -CHAIN BRANCHING," <i>Steroids</i> 41 (1983) 255-265.	
	11.	Wu et al., "Oral Progestogen Combined with Testosterone as a Potential Male Contraceptive," <i>J. Clin. Endocrinol. Metab.</i> 84 (1999) 112-122.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--